C6239
Cinalukast
~98% (HPLC)
别名:
(E)-4-[[3-(2-(4-Cyclobutyl-2-thiazolyl)ethenyl)phenyl]amino]-2,2-diethyl-4-oxobutanoic acid, Ro 24-5913
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C23H28N2O3S
化学文摘社编号:
分子量:
412.55
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
MDL number:
产品名称
Cinalukast, ~98% (HPLC)
InChI key
BZMKNPGKXJAIDV-VAWYXSNFSA-N
SMILES string
CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C3CCC3)c1)C(O)=O
InChI
1S/C23H28N2O3S/c1-3-23(4-2,22(27)28)14-20(26)24-18-10-5-7-16(13-18)11-12-21-25-19(15-29-21)17-8-6-9-17/h5,7,10-13,15,17H,3-4,6,8-9,14H2,1-2H3,(H,24,26)(H,27,28)/b12-11+
assay
~98% (HPLC)
form
solid
color
off-white
solubility
DMSO: >10 mg/mL
H2O: insoluble
originator
Roche
storage temp.
2-8°C
Quality Level
Gene Information
human ... CYSLTR1(10800)
Biochem/physiol Actions
Specific CysLT1 leukotriene receptor antagonist.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Studies of the combination of Ro 24-5913, a peptidoleukotriene antagonist, and Ro 24-4736, a PAF antagonist, in guinea pig and rat models of lung inflammation.
A F Welton et al.
Annals of the New York Academy of Sciences, 744, 274-288 (1994-11-15)
Synergism exhibited by LTD4 and PAF receptor antagonists in decreasing antigen-induced airway microvascular leakage.
M A Wasserman et al.
Advances in prostaglandin, thromboxane, and leukotriene research, 23, 271-273 (1995-01-01)
E Adelroth et al.
The Journal of allergy and clinical immunology, 99(2), 210-215 (1997-02-01)
The degree and duration of protection against exercise-induced bronchoconstriction afforded by three doses of a specific leukotriene D4 receptor antagonist, cinalukast, were assessed after an initial dosing and after 1 week of therapy. A placebo-controlled crossover study was performed in
Ro 24-5913: a potent, specific, orally active LTD4 antagonist.
M O'Donnell
Annals of the New York Academy of Sciences, 629, 413-415 (1991-01-01)
H Maehr et al.
Bioorganic & medicinal chemistry, 5(3), 493-496 (1997-03-01)
Structure optimization of the leukotriene D4 antagonist Ro24-5913 was attempted by combinatorial chemistry. Three segments in its N-succinyl-3-(2-thiazolylethenyl)anilide skeleton, designated as A, B, and C coincided with the thiazolyl, aniline, and N-acyl moieties, respectively, and were selected for variations in
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持